Marvell Technology
MRVL
335 hedge funds and large institutions have $6.33B invested in Marvell Technology in 2017 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 119 increasing their positions, 127 reducing their positions, and 40 closing their positions.
20% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 40
10% more capital invested
Capital invested by funds: $5.73B → $6.33B (+$602M)
1.43% more ownership
Funds ownership: 74.86% → 76.29% (+1.4%)
2% more call options, than puts
Call options by funds: $111M | Put options by funds: $109M
1% more funds holding
Funds holding: 332 → 335 (+3)
6% less repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 127
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$465M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$130M |
| 3 |
JP Morgan Chase
New York
|
+$83.7M |
| 4 |
Renaissance Technologies
New York
|
+$44.3M |
| 5 |
Jennison Associates
New York
|
+$35.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$118M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$104M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$69.7M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$59.1M |
| 5 |
IIM
Ivory Investment Management
New York
|
-$58.3M |
MRVL Hedge Fund Activity: Q2 2017 in Review
335 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Marvell Technology (MRVL) for Q2 2017, worth a combined $6.33B — up 10% from $5.73B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new MRVL positions and 40 closed out — a net gain of 8 holders — while 119 added to existing stakes and 127 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $465M. The largest seller was PFM Health Sciences, cutting an estimated $118M.
- 335 institutional investors held Marvell Technology (MRVL) as of Q2 2017, up from 332 in Q1 2017.
- Funds reported $6.33B of Marvell Technology stock for Q2 2017, up 10% quarter-over-quarter.
- 48 funds opened new Marvell Technology positions in Q2 2017 and 40 closed out, a net change of +8 holders.
- The largest Marvell Technology buyer in Q2 2017 was T. Rowe Price Associates, an estimated $465M added.
- The largest Marvell Technology seller in Q2 2017 was PFM Health Sciences, an estimated $118M sold.
Based on aggregated 13F filings for Q2 2017.